Mon, December 13, 2010
Sun, December 12, 2010
Fri, December 10, 2010
Thu, December 9, 2010
Wed, December 8, 2010
Tue, December 7, 2010
Mon, December 6, 2010
Fri, December 3, 2010
Thu, December 2, 2010
Wed, December 1, 2010
Tue, November 30, 2010
[ Tue, Nov 30th 2010 ]: Market Wire
2005 Certification
Mon, November 29, 2010
Thu, November 25, 2010
Wed, November 24, 2010
Tue, November 23, 2010
Mon, November 22, 2010
Sat, November 20, 2010
Fri, November 19, 2010
Thu, November 18, 2010
Wed, November 17, 2010

MannKind to Present at the Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference


  Copy link into your clipboard //health-fitness.news-articles.net/content/2010/ .. -cardiovascular-diabetes-obesity-conference.html
  Print publication without navigation Published in Health and Fitness on by Market Wire


VALENCIA, Calif.--([ BUSINESS WIRE ])--MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference on Wednesday, December 8, 2010 at 10:00 AM (PT) at the Nikko Hotel in San Francisco, CA.

Interested parties can access a link to the live webcast of the presentation from the News & Media section of the Company's website at [ http://www.mannkindcorp.com ].

About MannKind Corporation

MannKind Corporation (NASDAQ:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its diabetes pipeline includes AFREZZA® and MKC253. MKC253 is currently in phase 1 clinical trials. In March 2009, MannKind submitted an NDA to the FDA requesting approval of AFREZZA for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. In March 2010, MannKind received a Complete Response letter to this NDA from the FDA, requesting additional information. In July 2010, the FDA accepted MannKind's reply to the Complete Response letter and set a PDUFA action date of December 29, 2010. Other products in MannKind's pipeline include the cancer immunotherapy platform MKC1106, which is currently in phase 2 clinical trials. MannKind maintains a website at [ http://www.mannkindcorp.com ] to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.


Publication Contributing Sources

Publication Sponsors
[ Last Sunday ] - Oceanside Rental Gear